Enrichment of circulating tumor-derived extracellular vesicles from human plasma

Yoh, Kathryn E.; Lowe, Christopher J.; Mahajan, Shilpi; Suttmann, Rebecca; Nguy, Trung; Reichelt, Mike; Yang, Jenny J.; Melendez, Rachel; Li, Yijin; Molinero, Luciana; Ruppel, Jane; Xu, Wenfeng; Plaks, Vicki

doi:10.1016/j.jim.2020.112936

Cited by 24 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, EVs are secreted by almost every cell type, impairing tumor-specific DNA analysis [ 55 ]. For evDNA, some of these disadvantages may be compensated, e.g., by additional immune purification of tumor-specific sEVs [ 56 ], which are also the main fraction of EVs in our samples ( Figure 3 ). Interestingly, successful immune enrichment of tumor sEVs has been shown as a proof-of-concept study in PDAC patients for the analysis of KRAS mutations by ddPCR; however, further optimization is still required prior to clinical implementation [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients

Waldenmaier¹,

Schulte²,

Schönfelder³

et al. 2022

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinomas (PDACs) are tumors with poor prognosis and limited treatment options. Personalized medicine aims at characterizing actionable DNA variants by next-generation sequencing, thereby improving treatment strategies and outcomes. Fine-needle tumor biopsies are currently the gold standard to acquire samples for DNA profiling. However, liquid biopsies have considerable advantages as they are minimally invasive and frequently obtainable and thus may help to monitor tumor evolution over time. However, which liquid analyte works best for this purpose is currently unclear. Our study aims to directly compare tumor-, circulating free (cf-) and extracellular vesicle-derived (ev)DNA by panel sequencing of matching patient material. We evaluated copy number variations (CNVs), single nucleotide variants (SNVs) and insertions and deletions (indels). Our data show that evDNA contains significantly larger DNA fragments up to 5.5 kb, in line with previous observations. Stringent bioinformatic processing revealed a significant advantage of evDNA with respect to cfDNA concerning detection performance for SNVs and a numerical increase for indels. A combination of ev- and cfDNA was clearly superior for SNV detection, as compared to either single analyte, thus potentially improving actionable variant prediction upon further optimization. Finally, calling of CNVs from liquid biopsies still remained challenging and uninformative.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Similar considerations apply to tumor EVs. Here, detection or enrichment may be possible by tumor-specific markers such as glypican-1 [ 30 ] or using immune-enrichment [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients

Waldenmaier¹,

Schulte²,

Schönfelder³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In the clinic, some specific membrane markers and packaged proteins in TNBC cell-derived EVs, are estimable signatures for non-invasive diagnosis and prognosis of multiple cancers. Yoh et al (2021) collected the EpCAM+ EVs from the plasma of patients with non-small cell lung carcinoma (NSCLC) and TNBC. They subsequently confirmed that the heterogeneous EpCAM+ EVs were originated from tumor sites and demonstrated the clinical diagnostic potential value of cancer-EVs specific expressed biomarker, such as PD-L1.…”

Section: Extracellular Vesicles In Triple-negative Breast Cancer Diag...mentioning

confidence: 99%

Extracellular Vesicles: The Landscape in the Progression, Diagnosis, and Treatment of Triple-Negative Breast Cancer

Dong

Liu

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer (BC) with diverse biological behavior, high aggressiveness, and poor prognosis. Extracellular vesicles (EVs) are nano-sized membrane-bound vesicles secreted by nearly all cells, and are involved in physiological and pathological processes. EVs deliver multiple functional cargos into the extracellular space, including proteins, lipids, mRNAs, non-coding RNAs (ncRNAs), and DNA fragments. Emerging evidence confirms that EVs enable pro-oncogenic secretome delivering and trafficking for long-distance cell-to-cell communication in shaping the tumor microenvironment (TME). The transferred tumor-derived EVs modify the capability of invasive behavior and organ-specific metastasis in recipient cells. In addition, TNBC cell-derived EVs have been extensively investigated due to their promising potential as valuable biomarkers for diagnosis, monitoring, and treatment evaluation. Here, the present review will discuss the recent progress of EVs in TNBC growth, metastasis, immune regulation, as well as the potential in TNBC diagnosis and treatment application, hoping to decipher the advantages and challenges of EVs for combating TNBC.

show abstract

“…Tumor marker MUC1, although not specific, is highly expressed in lung cancer exosomes [78], so it could be an antigen for their selective isolation by immunoaffinity. Alternatively, the epithelial cell surface molecule (EpCAM) is a frequent surface biomarker targeted for plasma tumor exosome enrichment in different epithelial cancers, including lung cancer [22,79].…”

Section: Exosome Isolation and Identificationmentioning

confidence: 99%

Exosomes in Lung Cancer: Actors and Heralds of Tumor Development

Sandúa

Alegre

González

2021

Cancers

View full text Add to dashboard Cite

Lung cancer is a leading cause of cancer-related death worldwide and in most cases, diagnosis is reached when the tumor has already spread and prognosis is quite poor. For that reason, the research for new biomarkers that could improve early diagnosis and its management is essential. Exosomes are microvesicles actively secreted by cells, especially by tumor cells, hauling molecules that mimic molecules of the producing cells. There are multiple methods for exosome isolation and analysis, although not standardized, and cancer exosomes from biological fluids are especially difficult to study. Exosomes’ cargo proteins, RNA, and DNA participate in the communication between cells, favoring lung cancer development by delivering signals for growth, metastasis, epithelial mesenchymal transition, angiogenesis, immunosuppression and even drug resistance. Exosome analysis can be useful as a type of liquid biopsy in the diagnosis, prognosis and follow-up of lung cancer. In this review, we will discuss recent advances in the role of exosomes in lung cancer and their utility as liquid biopsy, with special attention to isolating methods.

show abstract

Enrichment of circulating tumor-derived extracellular vesicles from human plasma

Cited by 24 publications

References 45 publications

Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients

Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients

Extracellular Vesicles: The Landscape in the Progression, Diagnosis, and Treatment of Triple-Negative Breast Cancer

Exosomes in Lung Cancer: Actors and Heralds of Tumor Development

Contact Info

Product

Resources

About